These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8098178)

  • 1. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity.
    Gerlach J; Korsgaard S; Clemmesen P; Lauersen AM; Magelund G; Noring U; Povlsen UJ; Bech P; Casey DE
    Acta Psychiatr Scand; 1993 Apr; 87(4):244-52. PubMed ID: 8098178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders.
    Kim JH; Jung HY; Kang UG; Jeong SH; Ahn YM; Byun HJ; Ha KS; Kim YS
    Mov Disord; 2002 Nov; 17(6):1354-9. PubMed ID: 12465082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digital movement analysis, a new objective method of measuring tardive dyskinesia and drug-induced parkinsonian tremor: acceptability, reliability and validity.
    Nilsson FM; Hansen BL; Buchel C; Gattaz WF; Gerlach J
    Eur Arch Psychiatry Clin Neurosci; 1996; 246(2):71-7. PubMed ID: 9063911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research.
    Knol W; Keijsers CJ; Jansen PA; van Marum RJ
    J Clin Psychopharmacol; 2010 Feb; 30(1):57-63. PubMed ID: 20075649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.
    Sachdev P
    Aust N Z J Psychiatry; 2004 Jun; 38(6):445-9. PubMed ID: 15209837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curaçao Extrapyramidal Syndromes Study: I.
    van Harten PN; Matroos GE; Hoek HW; Kahn RS
    Schizophr Res; 1996 May; 19(2-3):195-203. PubMed ID: 8789918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curaçao Extrapyramidal Syndromes Study II.
    van Harten PN; Hoek HW; Matroos GE; Koeter M; Kahn RS
    Schizophr Res; 1997 Aug; 26(2-3):235-42. PubMed ID: 9323356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
    Modestin J; Wehrli MV; Stephan PL; Agarwalla P
    Schizophr Res; 2008 Mar; 100(1-3):97-107. PubMed ID: 18055180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders.
    Bergman J; Dwolatzky T; Brettholz I; Lerner V
    J Clin Psychiatry; 2005 Jan; 66(1):107-10. PubMed ID: 15669896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study.
    Weiden PJ; Mann JJ; Haas G; Mattson M; Frances A
    Am J Psychiatry; 1987 Sep; 144(9):1148-53. PubMed ID: 2888321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tardive dyskinesia and positive symptoms of schizophrenia.
    White T; Brown KW; Woods JP
    Acta Psychiatr Scand; 1991 May; 83(5):377-9. PubMed ID: 1677232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects.
    Kim JH; Byun HJ
    Clin Neuropharmacol; 2003; 26(6):312-6. PubMed ID: 14646611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia: results from Veterans Affairs Cooperative Study 394.
    Lohr JB; Caligiuri MP; Edson R; Lavori P; Adler LA; Rotrosen J; Hitzemann R
    J Clin Psychopharmacol; 2002 Apr; 22(2):196-200. PubMed ID: 11910266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
    Casey DE
    Schizophr Res; 1991; 4(2):109-20. PubMed ID: 1674881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.
    Gebhardt S; Härtling F; Hanke M; Theisen FM; von Georgi R; Grant P; Mittendorf M; Martin M; Fleischhaker C; Schulz E; Remschmidt H
    Eur Child Adolesc Psychiatry; 2008 Feb; 17(1):44-53. PubMed ID: 17876506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of extrapyramidal symptoms to age at onset and drug treatment in middle-aged and elderly schizophrenic patients.
    Srinivasan TN; Thara R; Padmavathi R; McCreadie RG
    Schizophr Res; 2001 Jan; 47(1):69-75. PubMed ID: 11163546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dyskinesia Identification System Condensed User Scale (DISCUS): reliability, validity, and a total score cut-off for mentally ill and mentally retarded populations.
    Kalachnik JE; Sprague RL
    J Clin Psychol; 1993 Mar; 49(2):177-89. PubMed ID: 8098048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.